Congress is unlikely to include many major health care priorities in the next government funding package; many adults continue to see racism as a problem across aspects of US society; the Endocrine Society will review its clinical guidelines for gender-affirming care.
Multiple sources determined that Congress is unlikely to include many major health care priorities in the next government funding package, according to The Hill. Only some of the programs facing imminent deadlines could be included in the legislation needed to fund the government by March 8, like community health center funding, a partial rollback of Medicare physician payment cuts, and a reversal of Medicaid cuts to hospitals serving low-income and uninsured patients. Conversely, although no final decisions have been made yet, potential reforms to the business practices of pharmacy benefit managers (PBMs) seem unlikely to make it into the funding package. According to Medriva, Congress has also decided not to include a site-neutral pay policy in the next funding package, which may potentially affect the cost of health care for millions of Americans. The site-neutral policy sought to eliminate hospitals from receiving higher payments than standalone physicians’ offices for the same outpatient services.
Despite increased calls to address racism in recent years, many adults continue to see racism as a problem across US society, according to a survey conducted by KFF Health News. The KFF Health News 2023 Racism, Discrimination, and Health Survey documents the implications and extent of racism and discrimination, particularly concerning people’s interactions with the health care system. The key takeaways included that most adults say racism is at least a minor problem in US politics, policing, criminal justice, housing, employment, and health care. Also, most adults across racial and ethnic groups trust doctors and health care providers to do what is right for them and their community all or most of the time. Conversely, Black adults are less likely to trust health care providers, but having more visits with providers who have a shared racial background or language is associated with higher levels of trust. These findings emphasized the importance of continued efforts to address systemic and structural racism across various aspects of society, particularly in policing, politics, and the criminal justice system.
The Endocrine Society, the major global medical association for endocrinologists, will review its clinical guidelines for gender-affirming care, according to CNN. These guidelines help the organization’s 18,000 members determine the best practices for providing care to those who are transgender and gender diverse. To update the guidelines, a committee consisting of both Endocrine Society members and non-members who are gender-affirming care experts will go through the latest findings to determine how to provide appropriate care to patients; it will take about 2 years to examine the material and about another year for the revised guidelines to come together. Although some US states recently restricted or banned such care, the society said this is a routine update not prompted by politics. Also, despite the political response to gender-affirming care, every major US medical association, including the American Medical Association and the American Psychiatric Association, agrees that gender-affirming care is clinically appropriate for children and adults.
Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL
July 30th 2025Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.
Read More
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older
July 29th 2025The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Read More